Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 53, Issue 10, Pages 4450-4456Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00502-09
Keywords
-
Categories
Funding
- NIH [AI071299, AI059176]
- DFG, Germany
- government of the HKSAR
- University Grants Committee Areas of Excellence Fund [AoE P/10-01/01-02-I, AOE/P-10/01-2-II]
- University Grants Council [HKUST 6493/06 M, 600507]
Ask authors/readers for more resources
Immunocompromised patients are at risk of developing toxoplasmosis, and although chemotherapy is available, standard treatments are often complicated by severe side effects. Artemisinin is a new highly potent antimalarial drug that has activity against Toxoplasma gondii in vitro. However, artemisinin derivatives have previously been ineffective in vivo using a rat model of toxoplasmosis. In the present study, the efficacy of several new artemisinin derivates was investigated for treatment of mice infected with the parasite Toxoplasma gondii. Artemiside and artemisone displayed better inhibition than either artemisinin or artesunate against the parasite in vitro. Artemiside and artemisone treatment controlled parasite replication in vivo, and mice survived the acute infection. In a murine model of reactivated toxoplasmosis, both drugs increased survival, although artemiside was more effective. These results indicate that these newer derivatives of artemisinin may have potential for treatment of toxoplasmosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available